| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Human GzmB concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human GzmB. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human GzmB and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human GzmB, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human GzmB. You can calculate the concentration of Human GzmB in the samples by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 9.38 pg/mL |
|---|---|
| Detection Range | 15.63-1000 pg/mL |
| Total Assay Time | 3 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Human |
| Detection Method | Sandwich |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Human GzmB in samples. No significant cross-reactivity or interference between Human GzmB and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 9.38 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 3 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Sandwich ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant GzmB standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression (2023) Journal of Hematology & Oncology. 10.1186/s13045-023-01507-4
Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer (2024) Journal of Extracellular Vesicles. 10.1002/jev2.12484
Extracellular Vesicles Derived From Streptococcus anginosus Aggravate Lupus Nephritis by Triggering TLR2‐MyD88‐NF‐κB Signalling in NK Cells (2025) Journal of Extracellular Vesicles. 10.1002/jev2.70134
Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia (2025) Advanced Science. 10.1002/advs.202511573
Cryoablation inhibits the recurrence and progression of bladder cancer by enhancing tumour‐specific immunity (2023) Clinical and Translational Medicine. 10.1002/ctm2.1255
Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma (2025) CLINICAL CANCER RESEARCH. 10.1158/1078-0432.CCR-24-4338
Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation (2024) CANCER LETTERS. 10.1016/j.canlet.2024.216964
Akkermansia muciniphila-derived outer membrane protein Amuc_1100 promotes acetylation of RING Finger Protein 181 promoter and mediates Autophagy Related 7 ubiquitination to activate CD8+ T cells in lung adenocarcinoma (2025) INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES. 10.1016/j.ijbiomac.2025.147773
COPS6 promotes tumor progression and reduces CD8+ T cell infiltration by repressing IL-6 production to facilitate tumor immune evasion in breast cancer (2023) ACTA PHARMACOLOGICA SINICA. 10.1038/s41401-023-01085-8
Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2 (2024) Science China-Life Sciences. 10.1007/s11427-024-2706-2
Aquaglyceroporin-7 ameliorates sorafenib resistance and immune evasion in hepatocellular carcinoma through inhibition of lipid accumulation (2025) CELLULAR AND MOLECULAR LIFE SCIENCES. 10.1007/s00018-025-05801-x
NK cell function down regulated by HMGB2 through ANGPT1/PI3K/AKT pathway and its effect on esophageal squamous carcinoma cells (2025) Frontiers in Immunology. 10.3389/fimmu.2025.1666199
DNA damage agents trigger iNKT cell-mediated elimination of AML cells through activation of NF-κB/HLA-DRB6/CD1d pathway (2025) BIOCHEMICAL PHARMACOLOGY. 10.1016/j.bcp.2025.117174
Novel nanoparticle-combined therapy through EGFR and PD-L1 blockade: PFPR-siRNA-mediated suppressing NSCLC proliferation via PDT and enhanced antitumor immunity (2025) COLLOIDS AND SURFACES B-BIOINTERFACES. 10.1016/j.colsurfb.2025.115284
Helicobacter pylori infection induces POU5F1 upregulation and SPP1 activation to promote chemoresistance and T cell inactivation in gastric cancer cells (2024) BIOCHEMICAL PHARMACOLOGY. 10.1016/j.bcp.2024.116253
SREBF2 enhances lipid metabolism and represses anti-tumor immune responses in cervical cancer by increasing ACAT2 (2026) Communications Biology. 10.1038/s42003-026-09678-9
Deubiquitinating Enzyme UCHL1 Modulates FHL2 to Block Ferroptosis and Counteract CD8+ T Cell Anti-Tumour Immunity in Lung Adenocarcinoma (2025) IMMUNOLOGY. 10.1111/imm.70057
Optimized patient-derived lung cancer organoids recapitulating the immune landscape for precision therapy evaluation (2026) CELLULAR ONCOLOGY. 10.1007/s13402-025-01158-2
IL-2 Combined with IL-15 Enhanced the Expression of NKG2D Receptor on Patient Autologous NK Cells to Inhibit Wilms’ Tumor via MAPK Signaling Pathway (2022) Journal of Oncology. 10.1155/2022/4544773
m6A-modified circZNF548 regulates exosomal miR-7108-3p to activate CD3+CD8+ T cells and suppress NSCLC growth by JMY (2025) BMC BIOLOGY. 10.1186/s12915-025-02355-z
Glypican-3 Upregulated by YTHDF1 in an m6A-Dependent Manner Interacts With MUL1 to Repress HSF1 Ubiquitination Degradation, Boost CD276 Transcription, and Mediate Immune Escape in Gastric Cancer (2026) FASEB JOURNAL. 10.1096/fj.202503106R
G2E3 Suppresses the Tumor-Killing Function of CD8+ T Cells in Hepatocellular Carcinoma by Boosting CLCN2 Ubiquitination (2026) FASEB JOURNAL. 10.1096/fj.202503004RR
Cholangiocarcinoma derived exosomes attenuate the anti-tumor functions of NK cells (2026) Scientific Reports. 10.1038/s41598-026-36706-9
Inhibition of neutrophil extracellular traps via the FGF19/ERK/IL-8 axis enhances immune therapy in MSS colorectal cancer (2026) CLINICAL IMMUNOLOGY. 10.1016/j.clim.2026.110664
TFDP1 activates SPC25-mediated glutamine metabolism to repress anti-tumor immunity of NK cells in lung adenocarcinoma (2025) Expert Review of Clinical Immunology. 10.1080/1744666X.2025.2524469
